Cocrystal Pharma (FRA:8CC) Cyclically Adjusted FCF per Share: €-2.50 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:8CC Cocrystal Pharma Inc FRA:8CC
23 GF Score
Price €0.86
! 3 Warning Signs
View Full Analysis

What is Cocrystal Pharma Cyclically Adjusted FCF per Share?

Cocrystal Pharma FRA:8CC 23 Cyclically Adjusted FCF per Share is €-2.50 as of Mar. 2026. GuruFocus rates FRA:8CC with a GF Score™ of 23/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Cocrystal Pharma's adjusted free cash flow per share for the three months ended in Mar. 2026 was €-0.147. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-2.50 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 25.60% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 19.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Cocrystal Pharma was 25.60% per year. The lowest was -2.80% per year. And the median was 8.30% per year.

As of today (2026-07-14), Cocrystal Pharma's current stock price is €0.855. Cocrystal Pharma's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was €-2.50. Cocrystal Pharma's Cyclically Adjusted Price-to-FCF of today is .


Cocrystal Pharma  (FRA:8CC) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Cocrystal Pharma Cyclically Adjusted FCF per Share Related Terms


Cocrystal Pharma Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Cocrystal Pharma's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cocrystal Pharma Cyclically Adjusted FCF per Share Chart

Cocrystal Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.23 -6.82 -5.21 -5.40 -2.61

Cocrystal Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.55 -3.07 -2.75 -2.61 -2.50

FRA:8CC vs HOOK, LNAI, CYCN: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Cocrystal Pharma's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cocrystal Pharma Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cocrystal Pharma's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Cocrystal Pharma's Cyclically Adjusted Price-to-FCF falls into.


FRA:8CC
23GF Score
Cocrystal Pharma Inc FRA:8CC
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cocrystal Pharma Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cocrystal Pharma's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.147/330.2130*330.2130
=-0.147

Current CPI (Mar. 2026) = 330.2130.

Cocrystal Pharma Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 -2.354 241.018 -3.225
201609 -1.433 241.428 -1.960
201612 -1.096 241.432 -1.499
201703 -0.983 243.801 -1.331
201706 -0.483 244.955 -0.651
201709 -0.907 246.819 -1.213
201712 -0.654 246.524 -0.876
201803 -0.831 249.554 -1.100
201806 -0.776 251.989 -1.017
201809 -0.741 252.439 -0.969
201812 -0.699 251.233 -0.919
201903 0.697 254.202 0.905
201906 -0.347 256.143 -0.447
201909 -0.495 256.759 -0.637
201912 -0.393 256.974 -0.505
202003 -0.594 258.115 -0.760
202006 -0.476 257.797 -0.610
202009 -0.545 260.280 -0.691
202012 -0.339 260.474 -0.430
202103 -0.254 264.877 -0.317
202106 -0.302 271.696 -0.367
202109 -0.564 274.310 -0.679
202112 -0.319 278.802 -0.378
202203 -0.436 287.504 -0.501
202206 -0.433 296.311 -0.483
202209 -1.105 296.808 -1.229
202212 -0.567 296.797 -0.631
202303 -0.362 301.836 -0.396
202306 -0.510 305.109 -0.552
202309 -0.247 307.789 -0.265
202312 -0.304 306.746 -0.327
202403 -0.408 312.332 -0.431
202406 -0.338 314.175 -0.355
202409 -0.454 315.301 -0.475
202412 -0.297 315.605 -0.311
202503 -0.267 319.799 -0.276
202506 -0.184 322.561 -0.188
202509 -0.106 324.800 -0.108
202512 -0.107 324.054 -0.109
202603 -0.147 330.213 -0.147

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-2.50 mean?
Cocrystal Pharma (FRA:8CC) has a Cyclically Adjusted FCF per Share of €-2.50 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cocrystal Pharma and its competitors.
Is Cocrystal Pharma's Cyclically Adjusted FCF per Share too high?
Cocrystal Pharma's current Cyclically Adjusted FCF per Share is €-2.50. Overall, Cocrystal Pharma has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Cocrystal Pharma's Cyclically Adjusted FCF per Share compare to HOOK and LNAI?
Cocrystal Pharma's Cyclically Adjusted FCF per Share of €-2.50 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Cocrystal Pharma and its competitors. Cocrystal Pharma's current Cyclically Adjusted FCF per Share is €-2.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cocrystal Pharma stock overvalued right now?
Cocrystal Pharma (FRA:8CC) has a current Cyclically Adjusted FCF per Share of €-2.50. The current Cyclically Adjusted FCF per Share is €-2.50. Cocrystal Pharma's overall GF Score™ is 23/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Cocrystal Pharma (FRA:8CC), the current Cyclically Adjusted FCF per Share is €-2.50 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cocrystal Pharma Business Description

Other Exchanges COCP:USA
Address 19805 North Creek Parkway, Bothell, WA, USA, 98011
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
23GF Score

Get the complete analysis for FRA:8CC

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.86
Price